59826-16-3

Usage

Medicinal use

Treatment of hepatitis C virus (HCV) infection

Drug class

Protease inhibitors

Function

Block a specific protein that the virus needs to replicate and survive in the body

Common side effects

Nausea, fatigue, headache, and skin rash

Contraindications

Use may be contraindicated in certain populations such as pregnant women or individuals with severe liver impairment

Safety and efficacy

It is important to consult a healthcare professional before using simeprevir to ensure its safety and efficacy.

Upstream product

• 59430-56-7 5,8-Dihydroxy-3,4-dihydro-2(1H)-quinolinone 
• 100-39-0 benzyl bromide 
• 79784-29-5 N-(2,5-dimethoxy-phenyl)-3-ethoxy-acrylamide 
• 102-56-7 2,5-dimethoxyaniline 
• 79784-30-8 5,8-dimethoxycarbostyril 
• 61306-74-9 5,8-dimethoxy-3,4-dihydrocarbostyril 

Downstream Products

• 65008-21-1 8-benzyloxy-5-(2-tetrahydropyranyloxy)-3,4-dihydrocarbostyril 
• 59826-17-4 8-benzyloxy-5-(2,3-epoxypropoxy)-3,4-dihydro-2(1H)-quinolinone 
• 373359-46-7 8-benzyloxy-(5S)-5-oxiranylmethoxy-3,4-dihydro-1H-quinolin-2-one 
• 59826-19-6 8-benzyloxy-5-(3-tert-butylamino-2-hydroxy-propoxy)-3,4-dihydro-1H-quinolin-2-one 
• 59826-21-0 5-(3'-sec-butylamino-2'-hydroxy)propoxy-8-benzyloxy-3,4-dihydrocarbostyril 
• 65008-26-6 8-benzyloxy-5-<3-(3,4-dimethoxyphenethylamino)-2-hydroxypropoxy>-3,4-dihydrocarbostyril 
• 80090-24-0 8-Benzyloxy-5-(2-hydroxy-3-isopropylamino-propoxy)-1-methyl-3,4-dihydro-1H-quinolin-2-one; compound with (Z)-but-2-enedioic acid 
• 80090-22-8 5-[3-(1,1-Dimethyl-2-phenyl-ethylamino)-2-hydroxy-propoxy]-8-hydroxy-3,4-dihydro-1H-quinolin-2-one; compound with oxalic acid 
• 65023-07-6 2-(5-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-2-hydroxy-propoxy}-2-oxo-1,2,3,4-tetrahydro-quinolin-8-yloxy)-acetamide; hydrochloride 
• 73642-16-7 8-benzyloxycarbonyloxy-5-<3-(N-benzyloxycarbonyl-3,4-dimethoxyphenethylamino)-2-hydroxypropoxy>-3,4-dihydrocarbostyril 
• 65008-90-4 8-acetoxy-5-<3-(3,4-dimethoxyphenethylamino)-2-hydroxypropoxy>-3,4-dihydrocarbostyril hydrochloride 
• 80090-28-4 [2-(3,4-Dimethoxy-phenyl)-ethyl]-{2-hydroxy-3-[2-oxo-8-(2-oxo-hexyloxy)-1,2,3,4-tetrahydro-quinolin-5-yloxy]-propyl}-carbamic acid benzyl ester 
• 65008-79-9 5-{3-[2-(3,4-Dimethoxy-phenyl)-ethylamino]-2-hydroxy-propoxy}-8-hydroxy-1-methyl-3,4-dihydro-1H-quinolin-2-one; hydrochloride 
• 80090-29-5 8-carboethoxymethoxy-5-<3-(N-benzyloxycarbonyl-3,4-dimethoxyphenethylamino)-2-hydroxypropoxy>-3,4-dihydrocarbostyril 

Relevant academic research and scientific papers

HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS

This invention provides compounds of Formula I having the structure U, V, W, X, and Y are as defined hereinbefore, or a pharmaceutically acceptable salt thereof, which are useful in treating or inhibiting metabolic disorders related to insulin resistance or hyperglycemia (typically associated with obesity or glucose intolerance), atherosclerosis, gastrointestinal disorders, neurogenetic inflammation, glaucoma, ocular hypertension and frequent urination; and are particularly useful in the treatment or inhibition of type II diabetes.

Novel substituted 4-aminomethylpiperidines as potent and selective human β3-agonists. Part 1: Aryloxypropanolaminomethylpiperidines

The synthesis and SAR of a series of human β3 adrenoreceptor agonists based on a template derived from a common pharmacophore coupled with 4-aminomethylpiperidine is described. Potent and selective agents were identified such as 26 that was in vitro active in CHO cells expressing human β3-AR (EC50=49 nM, IA=1.1), and in vivo active in a transgenic mouse model.

4-Aminopiperidine ureas as potent selective agonists of the human β3-Adrenergic receptor

The preparation and structure-activity relationships (SARs) of potent agonists of the human β3-adrenergic receptor (AR) derived from a 4-aminopiperidine scaffold are described. Examples combine human β3-AR potency with selectivity over human β1-AR and/or human β2-AR agonism. Compound 29s was identified as a potent (EC50 = 1 nM) and selective (greater than 400-fold over β1- with no β2-AR agonism) full β3-AR agonist with in vivo activity in a transgenic mouse model of thermogenesis.